LARP1 isoform expression in human cancer cell lines

Hagen Schwenzer(University of Oxford), Sarah P. Blagden(Churchill Hospital), Sarah Bonham(University of Oxford), Pia Neubert(University of Oxford), Andrew D. Beggs(University of Birmingham), Joanne Stockton(German Center for Neurodegenerative Diseases), Martin Fellermeyer(University of Oxford), Josephine Morris(University of Oxford), Mai Abdel Mouti(Nuffield Orthopaedic Centre), James Chettle(University of Oxford), Román Fischer(University of Oxford)
RNA Biology
April 14, 2020
10.1080/15476286.2020.1744320
Cited by 18

Related Papers

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F assembly on TOP mRNAs
|eLife|2017|201
Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies
|Clinical Cancer Research|2011|168